Clinical Trials Directory

Trials / Completed

CompletedNCT06390228

Impact of Hepatectomy on HCC Recurrence

Impact of Major Hepatectomy on Recurrence After Resection of Hepatocellular Carcinoma at China Liver Cancer Staging (CNLC) Stage : a Propensity Score Matching Study

Status
Completed
Phase
Study type
Observational
Enrollment
197 (actual)
Sponsor
Anhui Medical University · Academic / Other
Sex
All
Age
18 Years – 85 Years
Healthy volunteers
Not accepted

Summary

Hepatectomy is the first option for the treatment of hepatocellular carcinoma(HCC) at CNLC Ib stage. HCC patients who undergo curative hepatectomy may experience varying remnant liver volumes and thus leads to different oncological outcomes.

Detailed description

Patients with hepatocellular carcinoma (HCC) who undergo curative hepatectomy may experience varying remnant liver volumes. The investigators aimed to evaluate whether the extent of liver resection has an effect on postoperative recurrence in HCC patients. A retrospective analysis was conducted on 197 patients who underwent hepatectomy for a solitary HCC lesion measuring ≥5 cm between January 2019 and June 2022. Patients were divided into major hepatectomy (MAH) group (n=70) and minor hepatectomy (MIH) group (n=127) based on the extent of liver resection. Recurrence-free survival (RFS) was compared between the two groups. Propensity score matching was employed to mitigate potential biases in this research.

Conditions

Interventions

TypeNameDescription
PROCEDUREMajor hepatectomythe extent of liver resection

Timeline

Start date
2019-01-01
Primary completion
2023-08-01
Completion
2023-08-01
First posted
2024-04-30
Last updated
2024-04-30

Locations

1 site across 1 country: China

Source: ClinicalTrials.gov record NCT06390228. Inclusion in this directory is not an endorsement.